Replies to post #198897 on Biotech Values

[pollyvonwog]

On the other hand, MYL’s inability to get FDA approval for generic Copaxone to date may have gone a long way toward convincing MYL that MNTA has strong FoB technology and is a worthy FoB partner.

This is exactly my thinking for proposing the idea. Mylan intimately knows the difficulty in getting a Gx copaxone approved and also intimately knows MNTA through all the litigation (and I think CW mentioned he knows Heather Bresch pretty well cause of all those generic organizations their own together). Perhaps just coincidence, but 6 months ago is about when MYL stopped mentioned Gx all together (and seems like a fair amount of time ago that these talks would have started).